
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc has a current enterprise value of approximately $430 million, positioning it for significant long-term growth potential, particularly with a successful partnership with Novopro that could yield 8-10 times the current share price. The company's innovative drug candidates, notably SEP-786 and SEP-631, show promising results in preclinical trials, suggesting improved efficiency in clinical execution and the potential to rival established therapies like Xolair, which generated nearly $3.9 billion in sales in 2023. As Septerna advances its pipeline in key therapeutic areas, including endocrinology and immunology, the positive data surrounding its drug candidates enhances the firm's outlook and underscores the viability of its proprietary Native Complex Platform in the GPCR space.
Bears say
The financial outlook for Septerna Inc is hindered by several significant risks, primarily centered around potential delays in the advancement of its clinical candidates, specifically SEP-631, which could impact overall development timelines. Additionally, setbacks in clinical trials and challenges in securing necessary approvals for key products pose critical threats to the company’s future revenue prospects. Furthermore, the uncertainty surrounding its partnership with Novo Nordisk, coupled with risks of lower-than-expected market penetration rates and the potential for long-term dilution, further complicates the company's financial position.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares